about
P3354
ABL1 BCR-ABL T315IABL1 BCR-ABL E255KPDGFRA D842VABL1 BCR-ABL F317LABL1 BCR-ABL F359VABL1 BCR-ABL M244VABL1 BCR-ABL L248VABL1 BCR-ABL G250EABL1 BCR-ABL Q252HABL1 BCR-ABL Y253HABL1 BCR-ABL D276GABL1 BCR-ABL M351TABL1 BCR-ABL H396RABL1 BCR-ABL F486SABL1 BCR-ABL E255VABL1 BCR-ABL F359CABL1 BCR-ABL L384MABL1 BCR-ABL V299LABL1 BCR-ABL L387FPDGFRA V561DABL1 BCR-ABL E355GABL1 BCR-ABL F359IABL1 Q300RABL1 BCR-ABL E453AABL1 BCR-ABL V379IABL1 BCR-ABL A397PABL1 C475VABL1 N336SABL1 BCR-ABL L248RABL1 BCR-ABL E459K
P3355
A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaExplore the Synergy of Combination TKI TherapyMaximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571PDR001 Plus Imatinib for Metastatic or Unresectable GISTStudy of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to ImatinibPhase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) InhibitorInterleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) PatientsImatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell CancerPh II Study of Perifosine Plus Gleevec for Patients With GISTGleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic SyndromesEffect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate CancerImatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath TumorsEffects of Imatinib in Subjects With Seasonal Allergic Rhinitis and Who Are Sensitive to Timothy Grass PollenImatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerImatinib in Patients With Mucosal or Acral/Lentiginous MelanomaStudy Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)Effect of Food on Bioavailability of a Modified Release Formulation of ImatinibImatinib in Adult Patients With Metastatic Ocular MelanomaEffect of Food on Bioavailability of Modified Release Formulations of ImatinibImatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell TumorsEffect of Antacids on Gleevec® in Healthy VolunteersEffect of a Proton Pump Inhibitor on Gleevec® in Healthy VolunteersRegistration of Children With CML and Treatment With ImatinibSafety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal TumorsEfficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast CancerProspective Multicentric Randomized Study of Glivec® in Advanced GIST Expressing C-kit: Interruption After 5 Years vs MaintenanceA Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib TherapyEffects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)Pulmonary Hypertension and ImatinibLate Chronic Phase Chronic Myelogenous LeukemiaSorafenib for Imatinib/Sunitinib-failed GISTA Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-AlphaGlivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST PatientsRadotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase PatientsMasitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to ImatinibCrossover Study to Compare Pharmacokinetic Property of SYO-1126 and Glivec Film Coated Tab in Healthy Male Volunteers
P4844
Spotlight on imatinib mesylate in chronic myeloid leukemia.Expression of c-kit receptor in human cholangiocarcinoma and in vivo treatment with imatinib mesilate in chimeric miceImatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies.Use and limitations of imatinib mesylate (Glivec), a selective inhibitor of the tyrosine kinase Abl transcript in the treatment of chronic myeloid leukaemia.A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338Imatinib mesilate for the treatment of gastrointestinal stromal tumour.[Complete response achieved in a case of gastric gastrointestinal stromal tumor by administration of imatinib mesilate with concurrent relatively high-dose steroid therapy to control side effects].Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation.Interaction of imatinib mesilate with human P-glycoprotein.Treatment of hypereosinophilic syndrome with imatinib mesilate.[Preclinical and clinical profile of imatinib mesilate, a potent protein-tyrosine kinase inhibitor for CML therapy].[A case of chronic myelogenous leukemia responding to imatinib mesilate (Glivec) after relapse of blastic crisis following allogeneic bone marrow transplantation].Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway.[A case of recurrent gastrointestinal stromal tumor of the stomach with complete response to imatinib mesilate].Imatinib mesylate ameliorates the dystrophic phenotype in exercised mdx mice.On the ability of imatinib mesylate to inhibit smooth muscle cell proliferation without delaying endothelialization: an in vitro study.Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5'-phosphatase interaction with c-Abl.Cytotoxic Effects of Some Flavonoids and Imatinib on K562 Chronic Myeloid Leukemia Cell Line: Data Analysis Using the Combination Index MethodIntra-abdominal desmoid tumors mimicking gastrointestinal stromal tumors - 8 cases: A case reportLong-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience[Neoadjuvant therapy with imatinib mesilate for gastrointestinal stromal tumor of the stomach before subsequent successful surgical resection]Effect of imatinib mesilate on the disposition kinetics of ciclosporin in rats[A gastric stromal tumor (GIST) with a prolonged partial response to a reduced dose of imatinib mesilate][Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase][Recurrent neutrophilic panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib mesilate and dasatinib]An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Adult Patients With Ph + Leukemia (2004-08-31)
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
imatinib mesylate
@en
imatinibmesylat
@nn
mesylan imatynibu
@pl
type
label
imatinib mesylate
@en
imatinibmesylat
@nn
mesylan imatynibu
@pl
altLabel
imatinib methansulfonate
@en
imatinib monomesylate
@en
prefLabel
imatinib mesylate
@en
imatinibmesylat
@nn
mesylan imatynibu
@pl
P2175
P2868
P672
P486
P592
P661
P662
P665
P672
P683
P1579
P2067
589.247124
P2115
N0000148699
P2175
P2275
imatinib mesilate
@en
P231
220127-57-1